CALR and melanoma: It is known that induction of immunogenic cells death triggers exposure of CRT onto the cell surface [28, 29], but this is unlikely to play a role in the increased cell surface expression of CRT in vemurafenib-resistant melanoma cells, as these cells are viable and proliferative [43].